AtriCure Stock Soars 10.4% on Strong Q2 Revenue Growth

On July 30, 2025, AtriCure's stock surged by 10.4% in pre-market trading, reflecting a strong performance in the second quarter of the year.

AtriCure reported a significant increase in worldwide revenue, reaching $136.1 million, marking a 17.1% growth year-over-year. The company also noted an improvement in net loss and a substantial rise in adjusted EBITDA, alongside successful patient enrollment in the LeAAPS trial.

Key financial highlights include a 15.7% increase in U.S. revenue, driven by strong sales in key product lines such as the AtriClip FLEX·Mini device and the cryoSPHERE MAX probe. International revenue also saw a notable rise of 23.3%, indicating robust growth across various regions. Despite a slight decrease in gross margin, the company improved its net loss per share from $0.17 to $0.13 year-over-year.

Looking ahead, AtriCure has raised its financial outlook for 2025, projecting full-year revenue between $527 million and $533 million, with an expected adjusted EBITDA of $49 million to $52 million. The company anticipates continued growth and profitability, driven by its expanding portfolio and innovative technologies.